For emerging biotech companies, every milestone matters. Limited resources, investor expectations, and aggressive development timelines create constant pressure to move quickly without compromising quality or introducing risks that could delay progress to the clinic.
A practical roadmap from DNA to IND
In this e-book, our experts guide you through the six critical stages of biologics development, sharing practical strategies to help you accelerate progress, reduce risk, and make informed decisions on the path from DNA to IND.
In this e-book, you’ll discover:
- How to identify and de-risk the most promising biologic candidates before costly development challenges emerge.
- Why selecting the right expression system and vector strategy matters for speed, manufacturability, and future scalability.
- What separates a high-performing cell line from one that could limit your program later in development.
- How analytical, process and formulation development can strengthen your CMC package and support IND readiness.
- Strategies for accelerating toxicology material generation while maintaining quality and regulatory alignment.
- How early planning for GMP manufacturing and IND submission can help avoid delays and regulatory setbacks.
Whether your goal is to reach the clinic faster, maximize limited resources, or reduce development risk, this practical guide will help you move forward with greater clarity, confidence, and control.
Download the e-book to explore proven approaches for accelerating biologics development while minimizing risk on the journey to IND.
